Here, we review the current state of the art of CD19 CAR-T therapies for B-cell lymphomas, focusing on current updates in US FDA-approved products, along with their associated efficacy and toxicities. The gene discussed is CD19; the disease is B-cell non-Hodgkin lymphoma.